- Corporate
- Products
- For Print
- July 29, 2026
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta antibody “LEQEMBI®” (generic name: lecanemab) was JPY 29.3 billion for the first quarter of fiscal year 2026 (April 1, 2026 – June 30, 2026). In the same period of the previous fiscal year, the global revenue was JPY 23.1 billion, including the impact of stockpiling by distributors (estimated JPY 5.3 billion) in China.
By major markets, revenue came to JPY 15.4 billion in the United States, JPY 6.1 billion in Japan, and JPY 4.8 billion in China (in the same period last year: JPY 9.1 billion in the United States, JPY 5.5 billion in Japan, and JPY 7.7 billion in China).
This information is being disclosed in conjunction with today’s announcement of the financial results for the second quarter of 2026 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai’s financial results for the first quarter of fiscal year 2026, including details of LEQEMBI’s revenue, will be disclosed in Eisai's financial disclosure scheduled for August 3, 2026.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.